Why Maze Therapeutics, Up 55%, Was Shocked By Its Own Test Results

Core Insights - Maze Therapeutics' experimental treatment for phenylketonuria (PKU) exceeded expectations, leading to a significant surge in its stock price [1][4] - The treatment, MZE782, demonstrated a 39-fold increase in phenylalanine excretion with a single 960-milligram dose and a 42-fold increase with twice-daily 240-milligram doses [3][4] - The company plans to develop MZE782 for chronic kidney disease as well [4] Company Performance - Maze Therapeutics shares surged 51% to $24.19, reaching a record high after breaking out of a consolidation phase [4] - The company conducted a $150 million private placement, selling approximately 4 million shares at $16.25 each, with participation from notable investors [6] Clinical Results - The clinical trial involved 112 healthy adults, with no serious adverse events reported, indicating a favorable safety profile for MZE782 [5] - The results significantly surpassed Maze's own expectations of a 10-fold increase in phenylalanine excretion for PKU patients [4][5]